BioSpace: Biotech, Pharmaceutical and Clinical Research News
Dec 11, 2010 · The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few months later.
News - BioSpace
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM and her talks with Biogen, Gilead, Novavax and more; Wegovy’s higher dose induces more weight loss; AstraZeneca and Daiichi Sankyo’s Dato-DXd scores its first FDA approval.
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
Dec 16, 2024 · AbbVie on Friday announced that it will purchase immunology specialist Nimble Therapeutics for $200 million upfront as the pharma lays the groundwork for a comeback following its disappointing schizophrenia stumble.. Aside from the upfront consideration, which still remains subject to “certain customary adjustments,” according to Friday’s announcement, financial details of …
Parabilis Medicines™ – Formerly FogPharma - BioSpace
Oct 28, 2024 · BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
7 Indications for GLP-1s Beyond Weight Loss - BioSpace
Dec 23, 2024 · Last month, a real-world study linked Novo’s semaglutide with a 40% to 70% drop in the risk of Alzheimer’s disease in patients with type 2 diabetes, versus treatment with insulin.. A few months earlier, in July 2024, a Phase IIb study found that Novo’s older GLP-1 therapy liraglutide—marketed as Saxenda for obesity and Victoza for type 2 diabetes— could slow cognitive decline in ...
Camurus announces FDA approval of Brixadi™ for the ... - BioSpace
Camurus announces that the US Food and Drug Administration has approved Brixadi™ extended release injection for subcutaneous use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder, in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product.
Study Illuminates Possible Link Between COVID-19 and ... - BioSpace
Dec 19, 2021 · Adapted from ACS Chemical Neuroscience 2021, DOI: 10.1021/acschemneuro.1c00666. Scientists have pondered possible linkages between COVID-19 and the onset of Parkinson’s disease for more than a year.
Vertex Wins FDA Approval for New Cystic Fibrosis Option but
Dec 23, 2024 · Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product Alyftrek, clearing the biotech to market a product designed to improve on Trikafta.. William Blair analysts see the early approval of Alyftrek, which had a PDUFA of Jan 2., 2025, as a positive for the company’s stock, though it has yet to rebound from last week’s crash following disappointing results ...
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in
Dec 20, 2024 · GSK on Friday unveiled headline findings from the Phase III FIRST-ENGOT-OV44 study, posting mixed survival results for add-on Jemperli to standard-of-care chemotherapy and Zejula in patients with advanced ovarian cancer.. The pharma did not reveal specific data in its press release, announcing only that the FIRST trial hit its primary endpoint: Adding Jemperli, an anti-PD-1 antibody, led to ...
Phase III Clinical Trials - BioSpace
Jan 17, 2025 · The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.